Tim van de Hoef

Interventional Cardiologist at University Medical Center Utrecht

[EuroIntervention @EuroInterventio]

This study shows that coronary microvascular dysfunction, identified only by an impaired coronary flow reserve, was associated with increased rates of MACE and target vessel failure over a 5-year follow-up. #EAPCI https://t.co/8UpCJtbpEU

[Tim van de Hoef @drTPH]

@DrOzanDemir @JACCJournals @PCRonline @mmamas1973 @ColletCarlos @JGrapsa @JEscaned @habib_samady @MauroEchavPinto @WijnsWilliam @SVRaoMD @ncurzen Great effort Ozan, and congratulations on the publication! Still looking for robust data on diagnostic or prognostic value of sole microvascular resistance measurements in chronic coronary syndromes and ANOCA, and this may be part of the reason why….

[Shubha Deep Roy, MD, FACC, FASE, FASNC, FSCAI @SDRoyMD]

Summary of late-breaking clinical trials and science at #TCT2021. @crfheart @TCTMD
#ACCFIT #AHAFIT #ACCIC #ACCEarlyCareer

[Javier Escaned @JEscaned]

An analysis of the TWILIGHT-HBR substudy by @ANazmiCalik @elif_ilkay9 published at @PCRonline
https://t.co/9o4J1XRsW7
@shci_sec @CardioRed1 @IIS_IdISSC @CaoDavide @Drroxmehran

[Tim van de Hoef @drTPH]

@venkmurthy @drandrewsharp Under review for some time already, we hope to get this published soon. Much more come from this great collaboration.

[Matthias Götberg @MGtberg]

iFR and FFR with similar outcome at 5-years! No difference in any subgroup or components of the composite outcome. “iFR is quicker, easier, cheaper and with no discomfort for the patient. iFR lowers the threshold for performing physiology!” @DLBHATTMD @TCTConference

[Andrew Sharp @drandrewsharp]

Coronary Physiology Strikes Back?! ILIAS Registry shows that FFR guidance may be strengthened by the addition of coronary flow measurements in stable IHD. RCT needed here to change practice. #TCT2021

[Tim van de Hoef @drTPH]

@DrOzanDemir @venkmurthy @UKheartresearch @JEscaned @hect2701 @TCTConference @PCRonline @TCTMD @Guusdewaard @ncurzen @mmamas1973 @RicardoPetraco @MauroEchavPinto @h_evald Thanks for the support @DrOzanDemir! We hope to get this published soon.

[R. Jay Widmer @DrArgyle]

Event rates 1/2 w/ #iFR deferral vs #FFR per @jerd10 in LAD & #ACS

[Andrew Sharp @drandrewsharp]

Wow, this chap appears to have read the #ORBITA paper, the appendix and the refs, as well as the abstract, other tweets and TCTMD! Kudos. https://t.co/D9JiQ5N2am

[C. Michael Gibson MD @CMichaelGibson]

ORBITA trial: PCI significantly reduced ischemia but no improvement in exercise time compared to placebo procedure #TCTDenver

[C. Michael Gibson MD @CMichaelGibson]

Dr. Al-Lamee explains ORBITA: rand, sham-cntrl trial of PCI in pts w/CAD watch full interview here https://t.co/PgEf3QABNB #TCTDenver

[C. Michael Gibson MD @CMichaelGibson]

Dr. Al - Lamee discusses results of ORBITA Trial in this mornings press conference #TCTCDenver

[Andrew Sharp @drandrewsharp]

#ORBITA #tctdenver

[The BMJ @bmj_latest]

A substantial percentage of US journal editors received personal payments from industry and these payments were often large, finds #BMJResearch https://t.co/2HJRjeVqUr

[Andrew Sharp @drandrewsharp]

#orbita giant Rasha...

[Tim van de Hoef @drTPH]

@ZaherFanari @ajaykirtane @crfheart @GreggWStone @MartyMleon @Drroxmehran @CMichaelGibson @ZaherFanari @ajaykirtane First things first, ORBITA to be presented tomorrow! #TCT2017

[Mamas A. Mamas @mmamas1973]

Can't be right that 8 fold difference between operators for #radialfirst approach in STEMI. Not right for patients https://t.co/Q3uXymumti

[NL Heart Institute @NL_heart]

The call for the 2018 Einthoven dissertation prizes is open. Deadline 5-1-2018. Check our website https://t.co/CQoqLCsfkp for details.

[Sukh Nijjer @SukhNijjer]

Here’s a clearer picture. Deferring lesions in the LAD using FFR is associated with a doubling in clinical events compared to iFR #TCTDenver